Oncology · Endometrial CancerTrial Updateclinicalmid-term

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Mutant Endometrial Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/21/2026, 6:30:29 PM

Assessment confidence: 86% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase Ib trial for a combination therapy targeting RAS pathway mutations in endometrial cancer is significant as it may establish new treatment options in a niche market. Success could enhance the competitive positioning of Verastem and its collaborators in the oncology landscape, particularly in targeted therapies. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (22 high-relevance).

Strategic Assessment

Success in this trial may enhance the competitive profile of Verastem and its collaborators in the oncology space, particularly for targeted therapies. The strongest clinical anchor is A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Meta (ClinicalTrials.gov), sponsor/company relevance (roche). In Oncology · Endometrial Cancer, 6 regulatory and 4 competitive items passed relevance filtering for M.D.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial could position the involved agents as potential treatment options in a niche market of endometrial cancer with RAS mutations.

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA.

Key Risks

Elevated medium regulatory exposure for M.D. Anderson Cancer Center could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates positive safety and efficacy results, it could lead to increased market share for the involved agents in the endometrial cancer segment, potentially translating into substantial revenue growth.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Lead sponsor: Hoffmann-La Roche. The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on dosing recommendations and safety results as they may influence future development strategies.
Timeline shift beyond mid term would change urgency.
Outcome from Verified Clinical Benefit | Cancer Accelerated Approvals would change the regulatory/clinical read.
Outcome from Ongoing | Cancer Accelerated Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Meta
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

M.D. Anderson Cancer Center

Commercial impact

medium

If the trial demonstrates positive safety and efficacy results, it could lead to increased market share for the involved agents in the endometrial cancer segment, potentially translating into substantial revenue growth.

Regulatory impact

medium

The outcomes of this trial could influence future regulatory submissions and labeling for the involved therapies, particularly if they are shown to be effective in a previously underserved patient population.

What to watch

Monitor for updates on dosing recommendations and safety results as they may influence future development strategies.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.